Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Merck Serono brings electronic MS device to six more countries

RebiSmart works alongside the company's MSdialog web-based software
RebiSmart_Merck_Serono

Merck Serono has launched its RebiSmart self-injection device for patients with multiple sclerosis (MS) in six more countries.

The device will now be available in Spain, Greece, Hungary, Israel, Chile and Colombia, following initial launches in 14 countries in May.

Dr Steven Hildemann, chief medical officer and head of global medical affairs and global drug safety at Merck Serono, said: “With the introduction of MSdialog, we are offering a unique digital technology to provide people with MS a management system that can help them create a more open dialogue with their healthcare team.

After using the device to inject themselves RebiSmart is docked and wirelessly send treatment data such as injection times and doses to the MSdialog server.

The MSdialog system can also be used to prompt patients, via email or text message reminders, to take their medication and it periodically sends out health report questionnaires for patients to answer.

Merck's original RebiSmart was the first injection device in MS to record the date, time and dosage of injections to help healthcare professionals monitor patient adherence.

The device was first launched in countries including Germany, France, the UK and Sweden in May and Merck Serono will continue rolling it out during 2015.

19th November 2014

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics